View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
January 19, 2022

BiologyWorks’ trial of Covid-19 test matches lab results accuracy

The device provides results to patients and POC providers simultaneously in 45 minutes.

Digital healthcare platform firm BiologyWorks has announced that its k(now) handheld molecular testing device showed 99.1% accuracy with RT-PCR lab test results in a substantive Covid-19 clinical trial.

Conducted by Locus Medicus in Athens, Greece, the independent clinical study tested 330 asymptomatic and symptomatic Covid-19 patients.

The clinical laboratory staff collected two bilateral anterior nasal swabs from each patient for the trial.

One swab was tested in the handheld, reusable molecular test while the standard of care CE-Mark RT-PCR lab test was used for the other.

Findings showed that the molecular testing device was 99.1% accurate with the laboratory RT-PCR test results.

BiologyWorks k(now) molecular Covid-19 test is connected with the k(now) PRO digital platform, which provides a complete solution to point-of-care (POC) providers for end-to-end testing management.

The device provides results to patients and POC providers simultaneously in 45 minutes.

The company stated that the Los Angeles County Department of Health Services, the University of California Los Angeles (UCLA) and Streeklab in Haarlem, Netherlands, have also conducted independent studies on the BiologyWorks k(now).

Additionally, the molecular testing device’s efficacy was verified with more than 12,000 tests in the company’s Southern California laboratory.

All these studies confirmed that the device provides laboratory RT-PCR quality results.

BiologyWorks CEO Hunt Ramsbottom said: “Our company’s priority is to make lab-quality testing accessible, accurate and affordable for everyone.

“These clinical trials confirm that our handheld, reusable test is among the most accurate for Covid-19.

“We give individuals and providers a highly reliable testing platform, with significantly lower cost per result and shortened time to results.”

Related Companies

Free Report

Navigate your business through the ‘new normal’

COVID-19 continues to dominate headlines the world over. It has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities.  Faced with an explosion of conflicting information on how to plan and implement successful recovery strategies, decision-makers are in dire need of a single, reliable source of intelligence.   GlobalData’s COVID-19 Executive Briefing gives you access to unparalleled data and insights to successfully navigate the uncertain road to recovery across the world’s largest industries. Understand every aspect of this disruptive theme by delving into: 
  •  COVID-19 infection update, with statistics on the spread, testing by country, as well as the latest data on vaccines and therapeutic developments 
  • Economic impact overview, covering stock market indices, GDP, unemployment rates, policy responses & GlobalData’s economic recovery scorecards 
  • Sector developments, with access to sector insight summaries, cross-sector indices and the leaders and laggards in each industry vertical 
Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today. 
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy